Related Experiment Video

Updated: May 27, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells

Yan Zhou1, Jiyuan Yang, Jindřich Kopeček

  • 1Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.

Biomaterials
|December 6, 2011
PubMed

Insights

A novel N-(2-hydroxypropyl)methacrylamide (HPMA)-based drug delivery system selectively targets prostate cancer stem cells (CSCs). This polymer-conjugated cyclopamine retains bioactivity, reducing CSC viability and offering a promising therapeutic strategy for recurrent prostate cancer.

Area of Science:

  • Oncology
  • Polymer Chemistry
  • Drug Delivery

Background:

  • Prostate cancer recurrence and metastasis necessitate improved treatments.
  • Targeting cancer stem cells (CSCs) is a promising strategy due to their self-renewal and differentiation capabilities.
  • The hedgehog (Hh) signaling pathway is crucial for stem cell self-renewal, and its blockade by cyclopamine shows potential in prostate cancer regression.

Purpose of the Study:

  • To design and evaluate an N-(2-hydroxypropyl)methacrylamide (HPMA)-based cyclopamine delivery system for selective targeting of prostate CSCs.
  • To improve drug solubility and reduce systemic toxicity of cyclopamine.
  • To assess the anti-CSC efficacy of the polymer-conjugated cyclopamine.

Main Methods:

  • HPMA and N-methacryloylglycylphenylalanylleucylglycyl thiazolidine-2-thione were copolymerized using reversible addition-fragmentation chain transfer (RAFT) polymerization.
  • Cyclopamine was attached to the polymer via polymer-analogous reaction.
  • The selectivity and efficacy of the conjugate were evaluated on RC-92a/hTERT cells, an in vitro CSC model, assessing stem cell marker expression and prostasphere formation.

Main Results:

  • The HPMA-based delivery system successfully conjugated cyclopamine while retaining its bioactivity.
  • The polymer-conjugated cyclopamine demonstrated selectivity towards prostate CSCs.
  • Significant anti-CSC efficacy was observed, evidenced by decreased stem cell marker expression and reduced CSC viability.

Conclusions:

  • HPMA-based polymer-conjugated cyclopamine is a viable strategy for targeting prostate CSCs.
  • This approach offers improved drug solubility and reduced systemic toxicity.
  • The developed macromolecular therapeutic shows potential for overcoming prostate cancer recurrence and metastasis.

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...